QTERN SAVINGS AND SUPPORT

We want to help make it simple for your patients to start and stay on QTERN® (dapagliflozin and saxagliptin) with these savings and support offers.

HELP ELIGIBLE PATIENTS SAVE ON QTERN

Most of your eligible,‡ commercially insured patients will have a $0* co-pay with the QTERN Savings Card for as long as you prescribe QTERN.

Download Card

‡Savings subject to monthly limit. Subject to eligibility. Restrictions apply. Not available for government-insured patients.

Here’s how the QTERN Savings Card works

Your patients can start saving in 3 simple steps:

  • 1. Have a prescription for QTERN
  • 2. Download the QTERN Savings Card
  • 3. Present the card with a prescription to the pharmacist

For Mail Order: Call the number on the card and ask for Customer Service, or:

DOWNLOAD MAIL-IN REBATE

Repeat these steps each time you refill your prescription to receive your check.

ELIGIBILITY AND TERMS OF USE

ELIGIBILITY: You may be eligible for this offer if you are insured by commercial insurance and your insurance does not cover the full cost of your prescription, or you are not insured and are responsible for the cost of your prescriptions. Patients who are enrolled in a state or federally funded prescription insurance program are not eligible for this offer. This includes patients enrolled in Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD) programs or TriCare, and patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government-subsidized prescription drug benefit program for retirees. If you are enrolled in a state or federally funded prescription insurance program, you may not use this savings card even if you elect to be processed as an uninsured (cash-paying) patient. This offer is not insurance, is restricted to residents of the United States and Puerto Rico, and to patients over 18 years of age.

TERMS OF USE: Eligible commercially insured patients with a valid prescription for QTERN® (dapagliflozin and saxagliptin) who present this savings card at participating pharmacies will pay as low as $0 per 30-day supply subject to a maximum savings of $378 per 30-day supply. If you pay cash for your prescription, AstraZeneca will pay up to the first $150, and you will be responsible for any remaining balance, for each monthly prescription. Other restrictions may apply. Patient is responsible for applicable taxes, if any. Non-transferable, limited to one per person, cannot be combined with any other offer. Void where prohibited by law, taxed or restricted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. AstraZeneca reserves the right to rescind, revoke, or amend this offer, eligibility and terms of use at any time without notice. This offer is not conditioned on any past, present or future purchase, including refills. Offer must be presented along with a valid prescription at the time of purchase.

If you have any questions regarding this offer, please call 1-855-907-3133.

BY USING THIS CARD, YOU AND YOUR PHARMACIST UNDERSTAND AND AGREE TO COMPLY WITH THESE ELIGIBILITY REQUIREMENTS AND TERMS OF USE.

Pharmacist Instructions for a Patient with an Eligible Third Party:

For Insured/Covered Patients: Submit the claim to the primary Third-Party Payer first, then submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 8. This will reduce the eligible patient’s out-of-pocket costs to as low as $0 per 30-day supply subject to a maximum savings of $378. Reimbursement will be received from CHANGE HEALTHCARE.

For Insured/Not Covered Patients: Submit the claim to the primary Third-Party Payer first, if the primary claim submission shows a managed care restriction (step-edit, prior authorization or NDC block), continue the claim adjudication process and submit the balance due to CHANGE HEALTHCARE as a Secondary Payer COB with patient responsibility amount and a valid Other Coverage Code of 3. Eligible patients will receive a maximum savings of $378 per 30-day supply; patient’s out-of-pocket cost may vary. Reimbursement will be received from CHANGE HEALTHCARE.

Pharmacist Instructions for a Cash-Paying Patient: Submit this claim to CHANGE HEALTHCARE. A valid Other Coverage Code (eg, 1) is required. The card will cover up to $150 per 30-day supply. Reimbursement will be received from CHANGE HEALTHCARE.

Valid Other Coverage Code Required. For any questions regarding CHANGE HEALTHCARE online processing, please call the Help Desk at 1-800-422-5604.

FORMULARY COVERAGE OF QTERN

Formulary Search

Please select a state and county (optional) to find formulary information for {Brand_Name}. You can review tier status and managed care coverage for commercial, Medicare, and Medicaid plans.

Ajax error

JavaScript is required to access [Dynamic Service Title]

Please enable JavaScript in your browser settings.

Back to Home

Formulary FinderFormulary Finder

Qtern

Ajax error

HELP PATIENTS GET THE SUPPORT THEY NEED

Once you help your patients start, they might have questions as they continue taking QTERN. That’s where the Prescription Coverage Counselors can help.

phone

Prescription Coverage Counselors can answer questions about:

  • Benefit verification

  • Plan-specific prior authorization forms and appeals support

  • Other insurance forms

Monday – Friday

9 AM to 6 PM ET

1-844-846-2750

Important Safety Information for QTERN® (dapagliflozin and saxagliptin) and FARXIGA® (dapagliflozin)

Contraindications

  • Prior serious hypersensitivity reaction to dapagliflozin or saxagliptin

  • QTERN is contraindicated in moderate to severe renal impairment (eGFR <45 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis

  • FARXIGA is contraindicated in severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis

Warnings and Precautions

  • Pancreatitis: There have been postmarketing reports of acute pancreatitis in patients taking saxagliptin and in the SAVOR cardiovascular outcomes trial. Observe for pancreatitis. If pancreatitis is suspected, discontinue QTERN

  • Heart Failure: In the SAVOR cardiovascular outcomes trial, more patients treated with saxagliptin were hospitalized for heart failure compared to placebo. Patients with a prior history of heart failure or renal impairment had a higher risk for hospitalization for heart failure. Consider the risks and benefits of QTERN in patients who have known risk factors for heart failure. Monitor for signs and symptoms. If heart failure develops, consider discontinuation of QTERN

  • Hypotension: Dapagliflozin causes intravascular volume contraction and symptomatic hypotension can occur. Assess and correct volume status before initiating QTERN or FARXIGA in patients with impaired renal function, elderly patients, or patients on loop diuretics. Do not initiate in patients with an eGFR <60 mL/min/1.73 m2. Monitor for hypotension

  • Ketoacidosis has been reported in patients with type 1 and type 2 diabetes receiving dapagliflozin. Some cases were fatal. Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis regardless of blood glucose level. If suspected, discontinue QTERN or FARXIGA, evaluate and treat promptly. Before initiating QTERN or FARXIGA, consider risk factors for ketoacidosis. Patients on QTERN or FARXIGA may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis

  • Acute Kidney Injury and Impairment in Renal Function: Dapagliflozin causes intravascular volume contraction and renal impairment, with reports of acute kidney injury requiring hospitalization and dialysis. Consider temporarily discontinuing in settings of reduced oral intake or fluid losses. If acute kidney injury occurs, discontinue and promptly treat

    Dapagliflozin increases serum creatinine and decreases eGFR. Elderly patients and patients with impaired renal function may be more susceptible to these changes. Before initiating QTERN or FARXIGA, evaluate renal function and monitor periodically. Discontinue QTERN in patients if eGFR falls persistently below 60 mL/min/1.73 m2.

    FARXIGA is not recommended in patients with an eGFR persistently between 30 and <60 mL/min/1.73 m2.

  • Urosepsis and Pyelonephritis: SGLT2 inhibitors increase the risk for urinary tract infections (UTIs) and serious UTIs have been reported with dapagliflozin. Evaluate for signs and symptoms of UTIs and treat promptly

  • Hypoglycemia: Both saxagliptin and dapagliflozin can individually increase the risk of hypoglycemia when co-administered with insulin and insulin secretagogues. Consider lowering the dose of these agents when co-administered with QTERN or FARXIGA

  • Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): Rare but serious, life-threatening cases have been reported in patients receiving SGLT2 inhibitors including dapagliflozin. Cases have been reported in females and males. Serious outcomes have included hospitalization, surgeries, and death. Assess patients presenting with pain or tenderness, erythema, swelling in the genital or perineal area, along with fever or malaise. If suspected, institute prompt treatment and discontinue QTERN or FARXIGA

  • Hypersensitivity Reactions: Serious reactions have been reported in patients treated with saxagliptin, including anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with saxagliptin, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue QTERN. Use caution in patients with a history of angioedema to another DPP-4 inhibitor

  • Genital Mycotic Infections: Dapagliflozin increases the risk of genital mycotic infections, particularly in patients with prior genital mycotic infections. Monitor and treat appropriately

  • Increases in Low-Density Lipoprotein Cholesterol (LDL-C) occur with dapagliflozin. Monitor LDL-C and treat per standard of care

  • Bladder cancer: An imbalance in bladder cancers was observed in clinical trials. There were too few cases to determine whether the emergence of these events is related to dapagliflozin, and insufficient data to determine whether dapagliflozin has an effect on pre-existing bladder tumors. QTERN or FARXIGA should not be used in patients with active bladder cancer. Use with caution in patients with a history of bladder cancer

  • Severe and Disabling Arthralgia has been reported in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider discontinuing drug if appropriate

  • Bullous Pemphigoid: There have been postmarketing reports of bullous pemphigoid requiring hospitalization in patients taking DPP-4 inhibitors. Tell patients to report development of blisters or erosions. If suspected, discontinue QTERN

  • Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with QTERN or FARXIGA

Adverse Reactions

Most common adverse reactions reported in ≥5% of patients treated with QTERN were upper respiratory tract infection (13.6%), urinary tract infection (5.7%), and dyslipidemia (5.1%).

In a pool of 12 placebo-controlled studies, the most common adverse reactions (≥5%) associated with FARXIGA 5 mg, 10 mg, and placebo respectively were female genital mycotic infections (8.4% vs 6.9% vs 1.5%), nasopharyngitis (6.6% vs 6.3% vs 6.2%), and urinary tract infections (5.7% vs 4.3% vs 3.7%).

Drug Interactions

Strong CYP3A4/5 inhibitors (eg, ketoconazole): Co-administration with QTERN significantly increases saxagliptin concentrations. Do not co-administer QTERN.

Use in Specific Populations

Pregnancy: Advise females of the potential risk of QTERN or FARXIGA to a fetus especially during the second and third trimesters.

Lactation: QTERN or FARXIGA is not recommended when breastfeeding.

Indication and Limitations of Use for QTERN and FARXIGA

QTERN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM) who have inadequate control with dapagliflozin or who are already treated with dapagliflozin and saxagliptin. QTERN should only be used in patients who tolerate 10 mg dapagliflozin.

FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.

QTERN or FARXIGA is not indicated for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Please see US Full Prescribing Information pdf icon and Medication Guide pdf icon for QTERN.

Please see US Full Prescribing Information pdf icon and Medication Guide pdf icon for FARXIGA.

You may report side effects related to AstraZeneca products by clicking here.

References:

Reference:

  1. 1. QTERN [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  2. 2. FARXIGA [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  3. 1. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
  4. 2. QTERN [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  5. 3. FARXIGA [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  6. 4. Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab. 2015;100(5):1927-1932.
  7. 5. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509-514.
  8. 6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24(1):91-120.
  9. 1. QTERN [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  10. 1. QTERN [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  11. 2. Matthaei S, Catrinoiu D, Celiński A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38(11):2018-2024.
  12. 3. Matthaei S, Catrinoiu D, Celiński A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38(11)(suppl):2018-2024.
  13. 4. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009-2017.
  14. 1. QTERN [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  15. 2. Matthaei S, Catrinoiu D, Celiński A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38(11):2018-2024.
  16. 3. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009-2017.
  17. 1. QTERN [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.
  18. 2. FARXIGA [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.